A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Poliovirus vaccine live oral (Primary) ; Traneurocin (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms OPV-NA831
- Sponsors NeuroActiva
- 10 Sep 2020 New trial record
- 04 Sep 2020 According to a Biomed Industries media release, this study is expected to be started by end of November 2020 to the first quarter 2021.